Please assess the completion status of the following clinical trial:

Trial Title: Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Relapsed and/or refractory myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that meets certain criteria for prior treatments~* Have acceptable circulating blasts count~* Have clinically acceptable laboratory blood and urine test results~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Be able to swallow oral medications~* Have a life expectancy of 3 months or more~* Agree to use highly effective means of contraception during a defined period~* Negative serum pregnancy test before the start of the study drugs~* Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, provide a blood and bone marrow sample for genetic testing and agree to return for the required assessments~Exclusion Criteria:~* Have received cancer therapies within 14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug or have not recovered from toxicities from prior treatments~* Not recovered from toxicities related to allogeneic transplant~* Known active extramedullary central nervous system (CNS) AML~* Secondary cancer needing therapy with exceptions~* Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection~* Known significant mental illness or other condition that may affect the ability to follow the requirements of the study~* Have a chronic infection~* Have uncontrolled severe hypertension~* Have symptomatic congestive heart failure~* Have active angina pectoris or recent myocardial infarction~* Have chronic atrial fibrillation or unacceptable QTc~* Have had major surgery within 21 days of starting therapy~* Have additional uncontrolled serious medical or psychiatric illness~* Have any medical condition that would affect taking the study drug~* Receiving treatment with full dose warfarin~* Receiving treatment with drugs not allowed in this study~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CFI-400945 (Type: EXPERIMENTAL): CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).